Shanghai Medicilon Inc.

  On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list. Medicilon Preclinical Research (Shanghai) LLC, a subsidiary of Shanghai Medicilon Inc. (Medicilon), Nucleic Acid Drug R&D Service Platform was successfully selected!  This is the Science and Technology Commission of Shanghai Municipality's high recognition of Medicilon's technological innovation and R&D capabilities, and is also a spur and incentive for Medicilon to continuously improve its service levels. The Shanghai professional technical service platform is an important part of Shanghai's scientific and technological innovation service system. It is a scientific research entity built on the basis of enterprises, scientific research institutes, universities or other institutions with scientific and technological innovation capabilities.  ...

  Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene.  The strong support provided in collaboration projects has been recognized by client again. Medicilon and SicaGene: Go Deep Alone, Go Far Together The collaboration stems from a shared vision in the field of nucleic acid drugs.  Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties.  As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as  SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology.  SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, g...